MannKind Corporation has announced the resignation of Hakan Edstrom, who was the company’s President and CEO, as well as a director. In the wake of the resignation, Alfred Mann has been appointed interim CEO, effective November 19, 2015, and a board committee has begun a search for a new CEO.
Edstrom took over as CEO from Mann in January 2015, prior to Sanofi’s launch of MannKind’s Afrezza inhaled insulin, which took place in early February.
Read the MannKind press release.
published on
Featured event:
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
